InMed Pharmaceuticals Inc.
For the period ended Jun 30, 2025. Filed Sep 23, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Sep 23, 2025
INM$15.56+17.8%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| For the Year Ended | ||
|---|---|---|
| June 30, | ||
| 2025 | 2024 | |
| $ | $ | |
| Sales | 4,942,633 | 4,597,730 |
| Cost of sales | 3,236,047 | 3,496,817 |
| Gross profit | 1,706,586 | 1,100,913 |
| Operating Expenses | ||
| Research and development | 2,853,920 | 3,217,517 |
| General and administrative | 6,557,822 | 5,798,226 |
| Amortization and depreciation | 212,839 | 219,600 |
| Foreign Exchange Loss | 28,471 | 61,921 |
| Total operating expenses | 9,653,052 | 9,297,264 |
| Other Income (Expense) | ||
| Interest and other income | 155,882 | 527,901 |
| Finance expense | (371,549) | - |
| Loss before income tax expense | (8,162,133) | (7,668,450) |
| Income tax expense | - | (7,100) |
| Net loss for the year | (8,162,133) | (7,675,550) |
| Net loss per share for the year | ||
| Basic and diluted | (8.36) | (20.14) |
| Weighted average outstanding common shares | ||
| Basic and diluted | 975,985 | 381,053 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.